ECP
LGND icon

Elk Creek Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Elk Creek Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$17.9M Buy
394,740
+15,050
+4% +$853K 3.08% 3
2019
Q4 		$24.7M Sell
379,690
-167,821
-31% -$11.2M 2.84% 3
2019
Q3 		$34M Buy
547,511
+161,012
+42% +$10.1M 2.92% 4
2019
Q2 		$27.5M Buy
386,499
+50,153
+15% +$3.69M 2.06% 5
2019
Q1 		$26.4M Buy
336,346
+188,896
+128% +$14.3M 1.9% 6
2018
Q4 		$12.5M Buy
147,450
+46,039
+45% +$4.91M 1.04% 32
2018
Q3 		$17.4M Sell
101,411
-34,977
-26% -$5.27M 0.94% 37
2018
Q2 		$17.6M Sell
136,388
-26,406
-16% -$2.95M 0.97% 34
2018
Q1 		$16.8M Sell
162,794
-53,050
-25% -$5.25M 0.98% 32
2017
Q4 		$18.4M Buy
215,844
+6,003
+3% +$520K 1.08% 28
2017
Q3 		$17.8M Sell
209,841
-4,612
-2% -$365K 1.12% 29
2017
Q2 		$16.2M Sell
214,453
-21,889
-9% -$1.53M 1.05% 31
2017
Q1 		$15.6M Buy
236,342
+53,057
+29% +$3.49M 0.95% 40
2016
Q4 		$11.6M Sell
183,285
-15,970
-8% -$1.01M 0.78% 51
2016
Q3 		$12.7M Buy
+199,255
New +$14.6M 0.84% 46

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Elk Creek Partners's LGND Position: Q1 2020 in Review

Elk Creek Partners increased its Ligand Pharmaceuticals (LGND) stake by 4% in Q1 2020, buying an estimated $853K and bringing the position to 394,740 shares worth $17.9M. The position accounts for 3.08% of the portfolio, ranked #3.

Elk Creek Partners first reported a position in LGND in Q3 2016 and has held it in 15 quarters since. The position peaked at $34M in Q3 2019. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

  • Elk Creek Partners held 394,740 shares of Ligand Pharmaceuticals worth $17.9M as of Q1 2020.
  • Elk Creek Partners bought 15,050 Ligand Pharmaceuticals shares in Q1 2020, an estimated $853K.
  • Ligand Pharmaceuticals made up 3.08% of Elk Creek Partners's portfolio in Q1 2020, its #3 holding.
  • Elk Creek Partners first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 15 quarters since.
  • Elk Creek Partners's Ligand Pharmaceuticals position peaked at $34M in Q3 2019.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.